×

Error

There was a problem loading image LEKETlogo11870681_940029516055704_2554505469251269831_n.jpg
×

Message

fsockopen(): unable to connect to ssl://query.yahooapis.com:443 (php_network_getaddresses: getaddrinfo failed: Name or service not known)

 

 

 

Israeli pride.  An innovative development with regards to babies' twisted feet. Children orthopedics is evolving with no need for casts or surgery.

UNFO MED Company was introduced this week during the thirty-third Orthopedics Conference held in Tel-Aviv. The company was previously titled one of Israel's promising companies in the Med in Israel Conference.  

 

What are the various ways of treating Metatarsus Adductus? Introducing a unique, easy-to- use solution, developed and manufactured in Israel, which solves the problem perfectly. 

Metatarsus Adductus is common amongst babies and is usually caused by the position of the baby in the womb. The baby's feet look like two halves moon bending towards one another. Up until today there has been no effective solution to this problem. The common treatment is the use of a special splint or casting of the foot till the baby turns 9 months old.

 

The cast is changed once a fortnight. The casts are outdated and were originally designated for a graver problem called Clubfoot. Usually the cast or splint is used till the baby starts walking. This obsolete and awkward treatment leads many families and doctors to avoid treatment due to the cumbersome process of changing the casts once a fortnight which is performed by a specialist doctor at a hospital or qualified stuff at a special ward. This tiresome process also requires preparation prior to the hospital visit. The process lasts for weeks and weeks and also involves dealing with hygienic issues related to the baby's stool and urine. When plastic casts are used the changing of casts is done by sawing which might cause injuries to the baby's feet.

 

In other cases, doctors recommend physiotherapy sessions at home, hoping to achieve some improvement. In such cases the responsibility falls on the parents rather than on the doctor. In the worst case scenarios, parents are sent home, being told that "there is no need for treatment, it will improve by itself". Indeed, sometimes the problem is solved without treatment, but in most cases it doesn't. One can never know in which case the problem will resolve itself and in which case the baby will continue to suffer from the problem and its side-effects in the future.

 

We are proud to introduce: a new, easy-to-use and effective solution to Metatarsus Adductus, made in Israel.

A one-of-a-kind biomechanical shoe which completely solves the problem. It is light, simple and elegant and has a unique feature – the shoe is worn below the ankle.

UNFO MED Ltd. which developed the footwear is an ISO 13485-certified orthopedic company.

The company was founded by Dr. Izak Daizade, a specialist in the field of orthopedic surgery with over 35 years of experience in the field. UNFO MED is the manufacturer of the revolutionary orthopedic system for newborn feet. The system is based on the expertise of Dr. Daizada in pediatric surgery. Dr. Daizade developed a treatment for Metatarsus Adductus and Clubfoot in newborns and is nowadays promoting this revolutionary treatment.

 

 

According to the company's owners there is no longer a reason to make do with answers such as "it will be fine" or "perhaps the problem will go away with time". You no longer have to go through the exhausting archaic treatments or complicated surgeries. The most important thing is to identify the problem at an early stage and start treating it with UNFO Foot Brace, preferably before the child is 6 months old. At a later stage it is much more difficult and complicated to treat the problem and it might even be impossible to do so.

 

What could happen if the child is not treated at all?   

According to Dr. Daizade it might cause future side effects which are usually reflected in footwear fitting, frequent wear and tear of shoes, calluses, pains, toes deformation and other orthopedic and aesthetic problems. It is easier to deal with the problem when the babies are younger and their skeleton is softer. You don't need to take the risk and see what the future holds.

Dr. Daizade adds that he is very proud that Israeli children are the first to enjoy this innovative treatment.

 

For further information :

Tel: 03-5010383

Address: 52 Weizmann Street, Holon

 

Photos provided by UNFO MED

 

 

 

      

"Through KKL-JNF, the Elkeles family continues to be a partner in the shaping of Israel's destiny, and once a trail is blazed, many people can walk on it."
KKL-JNF awarded the 2013 Samuel and Paula Elkeles Outstanding Scientist in Medicine Prize to Dr. Orly Elpeleg, the Head of the Department of Genetic and Metabolic diseases at Hadassah, at a moving ceremony at Hadassah Hospital in Jerusalem on Tuesday November 19. KKL-JNF World Chairman Efi Stenzler reaffirmed the organization's commitment to continue awarding this important prize in the future.
 


L-R: Barbara Goldstein, Harry Elyashiv, Prof. Orly Elpeleg, Efi Stenzler & Dr. Avigdor Kaplan. 
Photo: Tania Susskind

"I would like to congratulate Professor Orly Elpeleg, who was chosen as this year's recipient of the Samuel and Paula Elkeles Outstanding Scientist in Medicine Prize. Israel's entire populace and all of humanity benefits from your success," said KKL-JNF World ChairmanEfi Stenzler at the Elkeles prize giving ceremony at Hadassah Hospital in Jerusalem. The ceremony, which took place on Tuesday, November 19 was attended by Hadassah personnel, family, friends and distinguished guests, including Ms. Barbara Goldstein, a member of the KKL-JNF Directorate and the Deputy Executive Officer of Hadassah's office in Israel.


KKL-JNF World Chairman Efi Stenzler. Photo: Tania Susskind

"Israel is at the forefront of technological and scientific endeavor," Mr. Stenzler continued, "and many of KKL-JNF's achievements in various fields are based on innovative research, from desert afforestation, to recycling 87% of the country's wastewater for agriculture usage, and much more. Through KKL-JNF, the Elkeles family continues to be a partner in the shaping of Israel's destiny, and once a trail is blazed, many people can walk on it." 

Dr. Ludwig Elkeles established the foundation in memory of his parents, the late Samuel and Paula Elkeles. The family had its origins in Berlin, but Ludwig and his parents left Germany for England in 1936 as the Nazi regime rose to power. After the Second World War, Elkeles, an economist by profession, returned to Germany, and throughout the years maintained a strong connection with Israel. Towards the end of his life, he expressed a wish to donate his personal fortune to an enterprise that would benefit the Israeli public. He chose KKL-JNF as the partner for his donation, which was used to fund numerous projects, including a recreation area and playground in the Jerusalem Forest, a scenic lookout at Kadesh Barnea in the Negev, and the Mitzpe Gvulot site in the Negev. Elkeles also wished his estate to be used for the creation of a special foundation in memory of his parents, which would present an annual award for medical research.


Prof. Orly Elpeleg with Dr. Avigdor Kaplan. Photo: Tania Susskind

Towards the conclusion of the ceremony, Mr. Stenzler surprised the audience when he returned to the podium to make an exciting announcement: "The Elkeles prize has been awarded to outstanding scientists for the past twenty-five years, but at the present time, there are insufficient funds to continue this tradition. However, in recognition of the importance of encouraging medical research, KKL-JNF has decided to commit itself to continue awarding the prize in the future," Stenzler declared, to loud applause from the audience. 

This year's prize recipient is Dr. Orly Elpeleg, head of the Department of Genetic and Metabolic diseases at Hadassah. Over the past decade, she has focused on gene discovery in a large number of rare disorders, and has published reports on 30 novel disease-associated genes. She has participated in extensive national and international collaborations and has coauthored over 140 peer-reviewed articles. 

Dr. Avigdor Kaplan, Director General of Hadassah Medical Organization, said that seeing children suffer is what motivated Professor Elpeleg to try and discover the reason for their diseases. "Many of us saw the movie that described how a small girl who couldn't walk was eventually able to dance thanks to Professor Elpeleg's research. The entire Hadassah family is very proud of her." 

Professor Yaakov Naparstek, Head of the Division of Medicine at Hadassah, thanked KKL-JNF and the Elkeles family for awarding the prize. "It is my firm belief that biomedical research should be conducted at medical centers like Hadassah, where it is possible to go from the research bench to the patient's bedside, and vice-versa. There are those who think that doctors who are also research scientists are a dying breed, but at Hadassah Hospital, we feel that this is critical to the future of medical research. Dr. Elpeleg's success proves just how important this is."


Hadassah Elkeles, neice of Samuel Elkeles Z"L. Photo: Tania Susskind

Hadassah Elkeles, Samuel Elkeles' niece, who represented the family, said that this year's ceremony was especially moving for her, because the recipient of the prize is a woman. She spoke about her family's history, and mentioned that her family had donated to KKL-JNF during the 1920s, when they lived in Europe. "I even showed the receipts to Mr. Stenzler. My uncle, who had originally intended to study medicine, was a great supporter of Israel and KKL-JNF. In this family tradition, my father's last words were, 'Next year in the Land of Israel.'" 

Professor Orly Elpeleg was very moved to receive the prize. "Every successful research project needs partners, so I would describe this as our rather than as my research. In the 1980s, there were three categories of children's diseases – infectious diseases, cancerous diseases and all the rest, which were largely ignored in the textbooks, so I decided to research them. We were looking for disease-infected genes, which was sort of like looking for a specific carp in the ocean. To date, we have discovered 30 such genes, findings that have enabled breakthroughs in treating various children's diseases. 

"There is no research without belief – belief in your own personal ability, belief in your partners, and belief in your goal. I want to thank KKL-JNF and the Elkeles family, not for choosing me for the prize, but for highlighting our research. It is an affirmation of us and of our work." 

Dr. Osnat Levtziyon-Korach, Director of the Hadassah University Hospital on Mount Scopus, presented the committee's reasons for this year's choice, and the ceremony, which was graciously facilitated by KKL-JNF's Rivka Rey, concluded with the presentation of the prize and a KKL-JNF certificate of appreciation to Professor Elpeleg.

 

 

 

Italian vegetable vendors have signed an agreement to grow potatoes in the Negev during the winter, with the aim of retaining a supply of fresh produce when the Italian cold does not enable growing

 

The European seed company, Germicopa, sent diploid potato seeds to Negev farmers, for them to grow during the winter, when whether conditions in Italy are not conducive for growing.  This joint venture is aimed at avoiding any severance of the marketing sequence, enabling Italy’s regions to enjoy fresh produce in the winter as well.

 

According to Abraham Rothstein, CEO of "Tozza" (representing Germicopa), this is a preliminary export of the species from Israel to Italy. The Italian vendors discovered the combination of good winter weather in the Negev and the quality of southern farming products.

 

The first transaction entails the export of 450 tons derived of the Negev fields.  In light of the demand for this species in Italy, measures will be taken to increase the scope of marketing next winter.

 

The diploid seeds were brought to Israel after joint planning by the Italian distributor and Negev farmers in Israel.  The diploid has a unique flavor and color that is loved by Italian consumers, especially in Sicily.  The species produces high yields and is suitable for mashed potatoes, gnocchi, filling pocket pastries, knishes and baking.

 

The Germicopa seeds are advanced hybrid seeds created under full growth control in isolated areas of the French Brittany region.

 

Rothstein adds that the Israeli market is very important to the Europeans, seeing that we serve as their vegetable barn during the winter, when the ground on the continent is frozen, preventing vegetable growth in open areas.  In the past, Europeans made do with vegetables that were stored since the summer or obtained through limited import, but as the standard of living improved in Russia and Eastern Europe, so did the demand for vegetables in the winter and spring.

 

 

 

 

 

SanDisk Ventures officially introduced itself on Sunday and called for opportunities to invest in Israeli companies at an investment event in the old city of Jaffa and Tel Aviv coast.

 

In the event, that was held as a conference, leading multinational corporates, as well as venture capitals and startups from the Israeli ecosystem, discussed the future of storage and the innovations taking place in the global enterprise cloud and mobile flash storage industry.

 

Among guests there were Drew Henry, SanDisk Senior Vice President and General Manager of the Mobile and Connected Solutions; Rene Hartner, SanDisk Senior Director, Corporate Strategy & Business Development,  David Flynn, PrimaryData CEO and ex founder and CEO of Fusion-IO; Riccardo Badalone, Diablo Technologies CEO; Bryan Bogensberger, Inktank CEO; Emil Alon, Pebbles Interfaces CEO and Oren Boiman of Magisto, CEO.

 

"We see Israel, as a leading hub of storage solution companies, technology and innovation," said Amir Fridman, SanDisk Director of Corporate Strategy & Business Development.

 

"SanDisk will be investing over $75 million dollars in select early- to mid-stage companies that demonstrate innovation across the spectrum of flash storage, from companies with solutions that enhance enterprise storage applications to companies that develop consumer products. By collaborating with SanDisk, these companies gain access to a broad product portfolio from a recognized leader in flash, world-class technical expertise, customer introductions and an expanded channel for their products and services".

 

In the last year, SanDisk announced five investments, 3 three in the US and 2 two in Israel, Pebbles Interfaces and Magisto.

 

Photo  Ifat Golan. from right: Drew Henry and Amir Fridman.

 

President Peres presented the million dollar Breakthrough Research and Innovation in Neurotechnology (B.R.A.I.N) prize to Brain Gate Research and Development for the creation of robotic arms for disabled people which are controlled by neural sensors

President Peres to the BrainGate team:

 

"Israel can become a world leading start-up nation in brain research. Just as we are world leaders in nanotechnology so we can become leaders in brain research"

 

The President of the State of Israel, Shimon Peres, presented a million dollar prize this morning to BrainGate Research team for groundbreaking research in neurotechnology (The Breakthrough Research and Innovation in Neurotechnology - B.R.A.I.N) at the international Braintech Israel 2013 Conference, hosted by Israel Brain Technologies (IBT), a non-profit organization inspired by the vision of President Peres. IBT is headed by Rafi Gidron and was founded in 2011 with the aim of making Israel a hub for brain research.

BrainGate provides hope for disabled people all over the world through the creation of robotic and prosthetic arms which are controlled by neural sensors. The development is at the cutting edge of brain research which can allow disabled people to walk again and regain use of their arms. The 10 finalists are from some of the world's leading institutions including MIT, Brown, UCLA, UCSF as well as Israeli researches from top universities and businesses in the field of healthcare. The finalists were chosen from 70 projects, from 11 countries across the world.

Upon presenting the prize President Peres said, "It’s a privilege to present this prize. It is the result of hard work. Personally I'm excited because a few years ago we turned Israel into a world leader in nanotechnology and now we must do the same with neurotechnology and brain science research. "Israel can become a world leading start-up nation in brain research. Just as we are world leaders in nanotechnology so we can become leaders in brain research"

The 10 Brain Prize Finalists:

Dr. Hagai Bergman

We have shown that closed loop adaptive deep brain stimulation (DBS) of the basal ganglia (the part of the brain which is affected during Parkinson’s and other brain diseases) is superior to current stimulation methods. We conclude that the basal ganglia can be observed and controlled, and suggest that closed loop adaptive DBS is the optimal treatment for a range of severe basal ganglia disorders including Parkinson’s disease, depression, obsessive-compulsive disorders and schizophrenia.

 

Dr. Edward Boyden, MIT

The brain is made out of an incredible number of cell types, which change in different ways to cause diseases, raising the question of how to identify optimal targets in the brain for therapeutic purposes, as well as how to resculpt the dynamics of the brain for clinical benefit.  We propose to adapt a technology that we and our collaborators developed earlier, optogenetics, which enables cells to be activated and silenced by light, towards the systematic identification of clinically relevant targets in the brain, and towards deployment as a fundamental new neuromodulation technique for treating brain disorders.

 

BrainGateTeam Led by Dr. John Donoghue

The BrainGate Research and Development team, based at Brown University with collaborators at the Massachusetts General Hospital, the Department of Veterans Affairs Medical Center (Providence, Rhode Island), Case Western Reserve University, and Stanford University, has demonstrated the first human uses of an implanted neural sensor and neural interface system to control robotic and prosthetic arms in three-dimensional space, in one case by a woman with tetraplegia who served herself a bottle of coffee nearly 15 years after a stroke. The BrainGate research, which previously resulted in the first human neural control of a computer cursor, has enabled a new understanding of human brain function and the development of a novel, fully-implanted platform neurotechnology capable of wirelessly transmitting large numbers of neural signals from multiple types of sensors for use in Brain Computer Interface, epilepsy monitoring, and neuromodulation applications.

ElMindA&Soterix (Collaboration)

About one third of the world’s population suffers from acute or chronic pain with the effects of pain exact a tremendous cost on health systems and impose emotional and financial burden on patients. Diagnostic and clinical management of pain still heavily rely on clinical symptoms and patient’s subjective reporting while the common treatment for pain is not based on personally customized pain relief. The proposed project (based on a multi-national collaboration) aims to develop a closed loop pain treatment platform, with the goal of offering a focused, specific and personalized approach for the effective treatment of pain.

 

Dr. Itzhak Fried

Brain pacemaker to treat memory impairment in early Alzheimer’s Disease and other memory disorders including traumatic brain injury, epilepsy and stroke.  Neurotechnology is based on site-specific, on-demand brain stimulation coupled to information processing and regulated by neural signal feedback.

Inscopix

Research on brain disease stands poised to achieve conceptual breakthroughs due to recent technological advances. There are now mice that provide models of human disease for study, tools to target specific brain regions, and ways to adjust certain patterns of brain functioning. However, science has yet to uncover the normal patterns of neural dynamics and how these go awry in disease states. Dr. Mark Schnitzer and the company he co-founded, (with Drs  KunalGhosh and Abbas El Gamal) InscopixInc, have created a technology to fill this gap by providing the necessary data to guide therapeutic strategies for re-tuning neural dynamics. Specifically, Inscopix has created brain imaging devices for use in freely behaving mice, by using mass producible optoelectronics, thereby enabling researchers to observe the dynamics of large numbers of individual, genetically identified neurons and in many mice in parallel. This innovation will yield crucial knowledge of how circuit dynamics differ between normal and diseased brains, a key toward creating corrective strategies.

 

Insightec

Focused ultrasound enables focal effects in the brain with sub millimeter accuracy with no impact to surrounding tissue using MRI image guidance.It is currently applied to the treatments of movement disorders (Parkinson’s and Tremor).Beyond that it is being evaluated as the world first noninvasive deep brain focused Neuromodulation technology which will revolutionize our understanding of the human brain.

 

Nano-Retina

Interfacing with retinal neurons, Nano Retina’s artificial retina prosthesis is designed to use the natural mechanisms of the eye to convert images into neural stimulation. Neural stimulation is delivered through more than 600 electrodes, which can be recognized by the brain, thereby restoring vision to persons blinded by retinal diseases, such as macular degeneration.

 

Dr. Andrew Schwartz

In the last 30 years we have developed an effective approach for decoding the intention component of volitional movement.  Using these results, we have now demonstrated the ability to translate recorded brain signals to coordinated, natural movement of a prosthetic arm and hand by a quadriplegic individual who uses this technology to perform tasks of daily living.

Team Led by Dr. Phillip Starr

By recording brain signals from the cortex in persons undergoing surgery for Parkinson’s disease, we recently discovered a biomarker of abnormal brain synchronization that can be detected using a clinically practical electrode that does not penetrate or damage brain tissue. Our next step is to utilize this signal to improve the effectiveness of neurostimulation therapies by incorporating feedback control.

 

 Photos Silvia Golan